Wedbush Maintains Outperform on Gossamer Bio, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Gossamer Bio (NASDAQ:GOSS) and raises the price target from $5 to $6.
November 10, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Gossamer Bio and raises the price target from $5 to $6.
The news of an analyst maintaining an Outperform rating and raising the price target typically indicates a positive outlook for the company. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100